Instrumental in formation of SynCardia Systems, Inc., maker of the CardioWest Temporary Total Artificial Heart (TAH-t) Polymer Chemistry, Assisted Devices. In July 2009, Dr Slepian was appointed chairman of the Science Advisory Board for MicroMed Cardiovascular, manufacturer of the HeartAssist 5™ ventricular assist device. The CardioWest (trademarked) TAH-t completely replaces the blood-pumping function of the diseased heart. For patients with end-stage congestive heart failure at imminent risk of death, this device has proven to be a life-saver, allowing them to be "bridged" and supported until a human heart transplant can be performed. He is recognized for his research and development of novel therapeutics. These include the use of polymeric biomaterials as tissue supports, barriers or means of local drug delivery in tubular organs or organ components, biodegradable stents, drug-eluting stents and the TAH.
The Arizona Board of Regents appointed Marvin Slepian, MD, a Regents’ Professor April 11, 2019.
The UA College of Engineering named Dr. Slepian a DaVinci Fellow. The award recognizes talented and resourceful faculty and provides a one-time grant of $10,000. Dr. Slepian plans to use the funds to support student research in his lab.
Dr. Slepian also received the Daniel Drake Award from his medical school, the University of Cincinnati College of Medicine. The award honors distinguished alumni.